iNeo-Vac-R01

BIOLOGICAL4 trials

Sponsors

Sir Run Run Shaw Hospital, Yifan Wang, Yinghua Xu

Conditions

Biliary Malignant TumorsDigestive System NeoplasmsHepatocellular Carcinoma (HCC)

Phase 1

Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen Alone in Subjects With Advanced Digestive System Neoplasms

RecruitingNCT06019702

Sir Run Run Shaw HospitalDigestive System Neoplasms

Start: 2023-09-08End: 2027-12-31Target: 20Updated: 2023-09-11

Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Combination With Standard First-line Treatment in Subjects With Advanced Digestive System Neoplasms

RecruitingNCT06026800

Sir Run Run Shaw HospitalDigestive System Neoplasms

Start: 2023-09-08End: 2027-12-31Target: 20Updated: 2023-09-11

Evaluation of the Safety, Tolerability and Efficacy of iNeo-Vac-R01, an Individualized mRNA Therapeutic Technology Based on Tumor Neoantigens, for Adjuvant Treatment in Patients With Biliary Malignant Tumors After Radical Resection

RecruitingNCT07368803

Yifan WangBiliary Malignant Tumors

Start: 2025-09-11End: 2027-09-30Target: 20Updated: 2026-02-03

A Clinical Study on the Safety, Tolerability and Efficacy of Neoantigen-based Personalized mRNA Therapy iNeo-Vac-R01 Plus PD-1 Inhibitor in Adjuvant Treatment of Liver Cancer Post Radical Resection

RecruitingNCT07495215

Yinghua XuHepatocellular Carcinoma (HCC)

Start: 2025-09-11End: 2028-12-31Target: 20Updated: 2026-03-27